Cimed sells Carmed in Portugal as Flavy and sets its sights on Latin America
Cimed exports its Carmed lip balm to Portugal as Flavy with 150,000 units and targets Mexico: the keys to its distribution model for operators.
The Brazilian pharmaceutical company Cimed began selling its Carmed lip balm in Portugal on October 6, rebranded as Flavy, with an initial batch of 150,000 units in the Wells pharmacy chain, which operates close to 300 stores, according to InfoMoney.
Carmed accounts for around 15% of Cimed's revenue, which in 2025 totaled more than 3,070 million reais, and sells about two million lip balms a month, according to Bloomberg Línea. The pharmaceutical company wants the international market to represent half of the brand's revenue within two years. Karla Felmanas, Cimed's vice president, told InfoMoney that Flavy is an international word, and Bloomberg Línea reported that Argentina, Colombia, Chile and Mexico appear among the markets with the greatest potential. For Mexico, the case matters because pharmacies and self-service retail are the natural channel for health consumption, and a Brazilian mass-market brand competes on the same shelf as local ones.
Flavy arrives with five scents, among them Açaí, Maçã do Amor, Água de Coco and two editions with the Fini candy brand. The suggested price in Portugal is 6 euros per unit, compared with the range of 19 to 27 reais in Brazil. Production remains at the Pouso Alegre plant in Minas Gerais, and the first batch took 60 days to reach Portuguese shelves, according to InfoMoney. Distribution runs through a local partner and sales are exclusive to Wells, a different model from Brazil, where Cimed controls its own distribution. The company is also negotiating bringing its collaboration with Coca-Cola to Portugal, which in Brazil is sold under license, according to Bloomberg Línea.
For a consumer health operator in Mexico, the question remains how much it costs to rebrand a product for export, what margin is ceded to the local distributor and how a premium price is sustained in the pharmacy channel. Cimed told InfoMoney that it is holding talks for Latin America, but that nothing is certain yet.
This article was written with the assistance of artificial intelligence from verified sources and reviewed by a human editor before publication.